Evidence map›Paper›PMID 41008612›Full record

ArticleBiomolecules2025

Isoniazid-Derived Hydrazones Featuring Piperazine/Piperidine Rings: Design, Synthesis, and Investigation of Antitubercular Activity.

Esma Özcan, Siva Krishna Vagolu, Rasoul Tamhaev, Christian Lherbet, Lionel Mourey, Tone Tønjum, Miyase Gözde Gündüz, Şengül Dilem Doğan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Esma ÖzcanDepartment of Basic Sciences, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.
Siva Krishna VagoluUnit for Genome Dynamics, Department of Microbiology, University of Oslo, 0316 Oslo, Norway.
Rasoul TamhaevLaboratoire de Synthèse et Physico-Chimie de Molécules d'Interêt Biologique, LSPCMIB, Université de Toulouse, CNRS, 118 Route de Narbonne, 31062 Toulouse, France.ORCID 0009-0003-9101-7042
Christian LherbetLaboratoire de Synthèse et Physico-Chimie de Molécules d'Interêt Biologique, LSPCMIB, Université de Toulouse, CNRS, 118 Route de Narbonne, 31062 Toulouse, France.ORCID 0000-0001-5427-5040
Lionel MoureyInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, 205 route de Narbonne, BP 64182, 31077 Toulouse, Cedex 4, France.ORCID 0000-0002-8259-1259
Tone TønjumUnit for Genome Dynamics, Department of Microbiology, University of Oslo, 0316 Oslo, Norway.ORCID 0000-0002-1709-6921
Miyase Gözde GündüzDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Sıhhiye, 06100 Ankara, Turkey.ORCID 0000-0002-2287-9509
Şengül Dilem DoğanDepartment of Basic Sciences, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.

Funding

Research Foundation of Erciyes University Research Foundation of Erciyes University
6 · The paper itself

Abstract

Isoniazid (isonicotinic acid hydrazide, INH) is a key drug used to treat tuberculosis (TB), which continues to be the world's most lethal infectious disease. Nevertheless, the efficacy of INH has diminished because of the emergence of

Indexed as

Antitubercular AgentsHydrazonesIsoniazidMycobacterium tuberculosisPiperazinePiperazinesPiperidinesBacterial ProteinsDrug DesignDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMolecular Docking SimulationOxidoreductasesAntitubercular AgentsBacterial ProteinsHydrazonesInhA protein, MycobacteriumIsoniazidOxidoreductasesPiperazinePiperazinespiperidinePiperidinesantimycobacterialcytotoxicityInhAmolecular modelingMycobacterium tuberculosisN-acylhydrazone

Identifiers

PMID41008612
PMCPMC12467433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.